Steatotic liver disease (SLD) has emerged as a prevalent and significant condition that contributes to the rising burden of liver diseases worldwide [1]. Given the increasing prevalence of SLD, it is imperative to investigate its clinical implications. SLD is not confined to hepatic dysfunction, and manifests as a systemic disorder. Patients with SLD often exhibit a higher prevalence of comorbid metabolic risk factors, including obesity and type 2 diabetes mellitus (DM), which increase their susceptibility to cardiovascular disease (CVD).
